LYSP Stock Overview
Lysogene S.A., a biopharmaceutical gene therapy company, focuses on the discovery and development of therapies for children with neurodegenerative lysosomal storage disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Lysogene S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.81 |
| 52 Week High | €2.06 |
| 52 Week Low | €0.81 |
| Beta | 0.68 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -78.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| LYSP | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -1.7% | -1.0% |
| 1Y | n/a | -19.2% | 6.9% |
Return vs Industry: Insufficient data to determine how LYSP performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how LYSP performed against the UK Market.
Price Volatility
| LYSP volatility | |
|---|---|
| LYSP Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.1% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: LYSP has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine LYSP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 21 | Karen Pignet-Aiach | www.lysogene.com |
Lysogene S.A., a biopharmaceutical gene therapy company, focuses on the discovery and development of therapies for children with neurodegenerative lysosomal storage disorders. Its clinical programs include LYS-SAF302, which is in Phase II/III clinical trial for the treatment of mucopolysaccharidosis type IIIA; and LYS-GM101 that is in Phase I/II trial for the treatment of GM1 gangliosidosis. The company has a collaborative research collaboration with the Weizmann Institute of Science for developing a novel AAV gene therapy approach for neuronopathic gaucher disease, parkinson disease, and other diseases.
Lysogene S.A. Fundamentals Summary
| LYSP fundamental statistics | |
|---|---|
| Market cap | €11.40m |
| Earnings (TTM) | -€13.61m |
| Revenue (TTM) | €6.95m |
1.6x
P/S Ratio-0.8x
P/E RatioIs LYSP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LYSP income statement (TTM) | |
|---|---|
| Revenue | €6.95m |
| Cost of Revenue | €0 |
| Gross Profit | €6.95m |
| Other Expenses | €20.56m |
| Earnings | -€13.61m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.79 |
| Gross Margin | 100.00% |
| Net Profit Margin | -195.81% |
| Debt/Equity Ratio | -200.2% |
How did LYSP perform over the long term?
See historical performance and comparison